Restylane® Eyelight is a specialized dermal filler containing Hyaluronic Acid (HA). One of its key advantages is that it has been approved by the U.S. FDA specifically for the improvement of infraorbital hollowing. However, the product should only be used for its approved indications and must be administered by a qualified physician following a thorough clinical assessment. Before considering treatment with Restylane® Eyelight, it is important to understand the key information provided below.
Restylane® Eyelight – A dermal filler developed for the Under-Eye area
Restylane® Eyelight is a Hyaluronic Acid-based dermal filler that has been approved by the U.S. FDA for the improvement of under-eye hollowing in patients over 21 years of age. The product is specifically indicated for injection into the under-eye region, particularly the area between the lower eyelid and the cheekbone, to effectively restore volume and improve the appearance of hollow or sunken under-eye contours.
Notably, Restylane® Eyelight has been officially approved by the U.S. Food and Drug Administration (FDA) for use in patients over 21 years of age. To emphasize and clearly distinguish this new indication for the under-eye area, the predecessor product Restylane-L was officially renamed Restylane® Eyelight.
From a formulation and technical standpoint, this filler contains 20 mg/mL of Hyaluronic Acid (HA) and 0.3% lidocaine to help reduce discomfort during the injection procedure.
A key feature of Restylane® Eyelight is its NASHA® technology, which creates a cross-linked Hyaluronic Acid gel manufactured using NASHA® technology. These characteristics are particularly important for the delicate under-eye area. However, temporary side effects such as swelling, bruising, pain, or mild irregularities at the injection site may still occur after treatment.
What indication has Restylane® Eyelight been approved for by the U.S. FDA?
According to the FDA approval letter and the Premarket Approval (PMA) supplement P040024/S135 for Restylane® Eyelight, the product is indicated for the improvement of under-eye hollowing in adults 21 years of age and older. Details are provided below:
| Criteria | Detail information |
| Product name | Restylane® Eyelight. |
| Indication | Improvement of under-eye hollowing |
| Eligible patients | Adults 21 years of age and older. |
| FDA approval date | May 8, 2023 |
| PMA number | P040024/S135 |
| Ingredients | 20 mg/mL Hyaluronic Acid (HA) and 0.3% lidocaine. |
| Treatment area | The under-eye area, specifically the region between the lower eyelid and the cheekbone. |
*Information is based on the U.S. FDA approval letter and Premarket Approval (PMA) supplement P040024/S135.
Note: This product is not indicated for the treatment of under-eye bags, pigmentation-related dark circles, excess skin, or all signs of aging around the eyes.
Restylane® Eyelight and the FDA’s specialized training requirements
Although Restylane® Eyelight has been approved by the U.S. FDA, the U.S. Food and Drug Administration (FDA) also imposes a strict requirement: “The manufacturer may distribute Restylane® Eyelight only to healthcare providers that ensure the injector has successfully completed the product-specific training program.” This means the manufacturer may distribute Restylane® Eyelight only to healthcare providers that ensure practitioners have completed the specialized training program developed specifically for this product.
FDA requirements:
- Develop, maintain, and regularly update a product-specific training program.
- Provide training on facial anatomy and vascular anatomy.
- Provide training on safe injection techniques.
- Train practitioners to recognize and manage adverse events, including intravascular complications.
- Submit the training program to the FDA for review and approval before implementation.
- Distribute the product only to healthcare providers that ensure practitioners have completed the required training program.
- Submit periodic reports on the implementation and effectiveness of the training program.
These FDA requirements are intended to support appropriate product use and help reduce, but cannot eliminate, the risk of serious complications. Therefore, before undergoing treatment with Restylane® Eyelight, you should ensure that the physicians performing the procedure have successfully completed the product-specific training program.
With this requirement in place, patients can feel confident when choosing Restylane® Eyelight for the correction of under-eye hollowing at Seoul Center Clinic, where the physicians have completed the required product-specific training program and obtained the corresponding certification.
Why should under-eye injections be performed by a qualified physician?
Under the FDA approval conditions, the manufacturer may distribute Restylane® Eyelight only to healthcare providers that implement the product-specific training program and ensure that injectors have completed the required training.
First, the skin beneath the eyes is significantly thinner and more delicate than other areas of the face. Beneath this thin layer lies a complex network of soft tissues and blood vessels. Proper anatomical assessment and appropriate injection techniques are essential to help minimize the risk of complications.
In addition, concerns around the eye area can vary considerably and require careful medical evaluation. Under-eye hollowing often does not occur in isolation. It may coexist with under-eye bags, excess skin, pigmentation disorders, or significant volume loss caused by aging. These conditions require a thorough assessment by a qualified physician to determine whether Restylane® Eyelight is an appropriate treatment option and to develop the most suitable treatment plan.
For this reason, not every under-eye concern, such as dark circles or tired-looking eyes, is suitable for treatment with this filler. A qualified physician must first make an accurate diagnosis, identify the underlying cause of the concern, and determine the most appropriate product or treatment approach for each patient.
Finally, the injection technique plays a critical role in both the safety and aesthetic outcome of under-eye treatment. If performed by an inexperienced injector, placing the filler in the wrong tissue plane, injecting at the wrong location, or using an inappropriate amount of filler may lead to undesirable outcomes. These may include prolonged swelling, visible filler beneath the skin, lumpiness, asymmetry between the eyes, or even serious vascular complications that may affect both aesthetic results and overall health.
Why does Seoul Center Clinic choose Restylane® Eyelight?
Seoul Center Clinic has chosen Restylane® Eyelight because it is an authentic product with a clear origin and has been approved by the U.S. FDA for the specific indication of improving under-eye hollowing. Before granting approval, the FDA thoroughly reviewed the available clinical evidence regarding the product’s safety and effectiveness.
More importantly, the use of Restylane® Eyelight is accompanied by rigorous product-specific training requirements, requiring practitioners to receive training in facial anatomy, vascular anatomy, injection techniques, and the recognition and management of adverse events. The physicians who perform Restylane® Eyelight treatments at Seoul Center Clinic have completed the required product-specific training program, allowing patients to undergo treatment with confidence.
In addition, to maximize patient safety and protect patient interests, all Restylane® Eyelight products used at Seoul Center Clinic are genuine products. Patients are invited to personally inspect the product’s sealed packaging, labels, and overall condition before the treatment begins.
Furthermore, every treatment at Seoul Center Clinic is personalized to each patient. During the consultation, qualified physicians perform a thorough assessment of the under-eye anatomy and facial structure. Based on each patient’s individual concerns and facial characteristics, the physician develops a customized treatment plan designed to achieve the most natural-looking results. After the procedure, patients receive detailed aftercare instructions and are scheduled for follow-up visits to monitor recovery and help ensure a safe and smooth healing process.
Overall, the selection of Restylane® Eyelight reflects Seoul Center Clinic’s commitment to using products with clear origins and well-defined clinical indications. Every patient undergoes an individual assessment by a qualified physician to determine the underlying cause of under-eye hollowing before a treatment plan is recommended. Therefore, if you are experiencing under-eye hollowing and would like to rejuvenate this area for a more refreshed appearance, you may consider Restylane® Eyelight treatment at Seoul Center Clinic.
Frequently asked questions
1. When was Restylane® Eyelight approved by the FDA?
Restylane® Eyelight was approved by the U.S. Food and Drug Administration (FDA) on May 8, 2023. This approval officially authorized the product for the improvement of under-eye hollowing.
2. What treatment area is the product FDA-approved for?
Restylane® Eyelight is FDA-approved for injection into the under-eye area, specifically the region between the lower eyelid and the cheekbone, to improve the appearance of under-eye hollowing.
Does Restylane® Eyelight treat dark circles?
No. Restylane® Eyelight is not FDA-approved for the treatment of pigmentation-related dark circles. It is approved only for the correction of under-eye hollowing caused by volume loss.
However, if dark circles are primarily caused by the shadowing effect of deep tear troughs, restoring volume with Restylane® Eyelight may help the under-eye area appear smoother, brighter, and less tired. To determine whether this treatment is appropriate for your condition, you should consult a qualified physician at Seoul Center Clinic.
3. Are under-eye hollowing and eye bags the same?
No. Under-eye hollowing and eye bags are two different conditions, although both occur beneath the eyes and may contribute to a tired appearance.
Under-eye hollowing is caused by volume loss, typically due to fat atrophy or changes in the underlying bone structure, resulting in a sunken appearance. In contrast, eye bags are caused by excess volume, such as protruding fat, weakened supporting tissues, or fluid retention, creating a bulging appearance beneath the lower eyelid.
4. Who is a suitable candidate for Restylane® Eyelight?
Restylane® Eyelight is intended for adults 21 years of age and older who have under-eye hollowing caused by volume loss and are seeking a non-surgical facial rejuvenation option.
To determine whether the product is appropriate, a qualified physician should first evaluate your condition and rule out other causes of dark circles or under-eye bags that are unrelated to volume loss.
5. Who should not receive Restylane® Eyelight?
Restylane® Eyelight is contraindicated in individuals with a history of severe allergies, anaphylaxis, or multiple severe allergies; those with allergies to Gram-positive bacterial proteins; or those who are allergic to lidocaine or other amide-type local anesthetics.
If the planned injection site has acne, rashes, hives, cysts, skin injuries, or an active infection, treatment should be postponed until the area has fully healed.
Patients with bleeding disorders or those taking medications such as aspirin, warfarin, or other drugs that prolong bleeding should inform their physician, as these medications may increase the risk of bruising and bleeding at the injection site.
The safety of Restylane® Eyelight has not been established in pregnant or breastfeeding women. The product is indicated for adults over 21 years of age. Individuals receiving immunosuppressive therapy or those with relevant medical conditions should undergo a thorough medical evaluation before considering treatment.
6. Can Restylane® Eyelight cause side effects?
Yes. Restylane® Eyelight may cause temporary side effects after injection, including swelling, redness, bruising, mild pain, and itching at the injection site. In clinical studies submitted to the FDA, most reactions were mild and resolved within 7 days. However, in some cases, these reactions lasted 8 to 28 days.
7. How long do the results last?
The effects of Restylane® Eyelight are temporary. According to the clinical study submitted to the FDA, 64% of participants continued to show improvement in under-eye hollowing at 12 months. Actual duration may vary depending on the patient’s baseline condition, the amount of product injected, the injection technique, and individual metabolism. Whether additional treatment is needed should be determined through an evaluation by a qualified physician.
8. Why is specialized training required for practitioners?
As part of the FDA approval requirements, practitioners who administer Restylane® Eyelight must complete product-specific training. This training is intended to strengthen their understanding of facial and vascular anatomy, appropriate injection techniques, and the management of potential adverse events. It also equips physicians to recognize and manage potential adverse events promptly, particularly serious vascular complications that may occur during treatment of the delicate under-eye area.
Restylane® Eyelight may be considered for improving infraorbital hollowing in appropriately selected patients over 21 years of age. With its advanced NASHA® gel technology, the product provides natural-looking structural support with long-lasting results and requires little to no downtime. If you are concerned about under-eye hollowing, contact Seoul Center Clinic at 1800 3333 to schedule a consultation with one of our dermatologists, who can identify the underlying cause of your concern and recommend the most appropriate treatment.
Comment on the post